A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510301-18-00

Acronym

42756493CAN2002

Enrollment

Registered

2024-03-15

Start date

2019-12-05

Completion date

Unknown

Last updated

2025-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumors (other than Urothelial tumors), and FGFR gene alterations.

Brief summary

For Broad Panel Cohort and Core Panel Cohort: The proportion of subjects who achieve a complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) (RECIST v1.1.) or Response Assessment in Neuro-Oncology (RANO) as assessed by IRC., Pediatric Cohort: The proportion of subjects who achieve a CR or PR based on RECIST v1.1 or RANO as assessed by IRC

Interventions

DRUGJNJ-42756493

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
For Broad Panel Cohort and Core Panel Cohort: The proportion of subjects who achieve a complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) (RECIST v1.1.) or Response Assessment in Neuro-Oncology (RANO) as assessed by IRC., Pediatric Cohort: The proportion of subjects who achieve a CR or PR based on RECIST v1.1 or RANO as assessed by IRC	—

Measure

Time frame

—

Countries

Germany, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026